Change of Director's Interest Notice SW
Released
Released
Announcement PDF
ASX/Media Release
16/11/2020
Change of Director’s Interest Notice
Emyria Limited (ASX: EMD) (“Emyria” or “the Company”), a company that accelerates treatment
development for patients with unmet needs, is pleased to advise that Chairman, Stewart Washer, has made
various on-market purchases of shares in the Company.
A Change of Director’s Interest Notice is annexed to this announcement.
Emyria’s Chairman, Dr Stewart Washer, said: “It is an exciting and transformational period for Emyria.
Medicine is evolving rapidly with digital health but there’s a constant need for new, safe and effective
treatments. Emyria is ahead of the pack in treating patients who have been sick for a long time and are not
getting better with current care. We do this by using innovative treatments, like cannabinoids, and by using
digital health technologies. Emyria can monitor patients, collect evidence and contribute to improving these
new treatments. I’m highly optimistic about the path ahead for Emyria, and look forward to rolling out our
products and technologies globally into 2021.”
Emyria’s Managing Director, Dr Michael Winlo, said: “Dr Washer is a respected executive, leader and
investor and his most recent purchase of additional shares is a strong endorsement of our team, our work
and our future potential. Emyria is fortunate to be backed by a great Board on our quest to bring innovative
new treatments to patients sooner while also delivering value for our shareholders.”
Release authorised by:
Stewart Washer
Chairman
For further information
Dr Michael Winlo
Managing Director
(08) 6559 2800
mwinlo@emyria.com
Lexi O’Halloran
Media/Investor Relations
+ 61 (0) 404 577 076
lexi@janemorganmanagement.com.au
About Emyria (www.emyria.com)
Emyria Limited creates clinical evidence that accelerates the development of new treatments for patients with unmet
needs. Emyria achieves this by analysing the high quality clinical data gathered from its specialist clinical network –
Emerald Clinics (www.emeraldclinics.com.au) – and turning that into Real-World Evidence (RWE). Emyria’s data
supports the development and registration of new and promising treatments for patients with unmet medical needs by
providing unique, real-world insights into the safety, quality and efficacy of those unapproved treatments, in real
patients in the community. Emyria’s data assets are also a source of unique IP for Emyria, which along with its remote
patient monitoring technologies, data platforms and care models, further improve the quality of its RWE data assets
and insights as well as the care provided to patients.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, the company’s
strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and
similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important factors, including: the Company’s ability to
successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability
to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this
press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events
and developments will cause the Company’s views to change. However, while the Company may elect to update these
forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.
These forward-looking statements should not be relied upon as representing the Company’s views as of any date
subsequent to the date hereof.
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.s
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given
to ASX become ASX’s property and made be made public.
Introduced 30/09/2001
Name of entity:
Emerald Clinics Limited
ABN:
625 085 734
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director:
Stewart Washer
Date of last notice:
17/03/2020
Part 1 - Change of director’s relevant interests in securities
Note: In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust. In the case of a
company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
Direct or indirect interest
Direct and Indirect
Nature of indirect interest (including
registered holder)
Dr Stewart James Washer & Dr Patrizia Derna
Washer <The Washer Family Superannuation
Fund>
(Dr Washer is a trustee and beneficiary of the
Note: Provide details of the circumstances giving rise to
the relevant interest.
superannuation fund)
Dr Stewart James Washer & Dr Patrizia Derna
Washer <The Washer Family Trust>
(Dr Washer is a trustee and beneficiary of the Trust)
Mal Washer Nominees Pty Ltd <Mal Washer
Family A/C>
(Dr Washer is a trustee and beneficiary of the trust)
Date of change
No. of securities held prior to change
09/11/2020
10/11/2020
11/11/2020
12/11/2020
Dr Stewart James Washer & Dr Patrizia Derna
Washer <The Washer Family Superannuation
Fund>
(Dr Washer is a trustee and beneficiary of the
550,599 Ordinary Shares ( +100 shares correction)
Dr Stewart James Washer & Dr Patrizia Derna
Washer <The Washer Family Trust>
28,400,000 Ordinary Shares
1,500,000 Unlisted Options
superannuation fund)
(Dr Washer is a trustee and beneficiary of the Trust)
+ See chapter 19 for defined terms
exercisable at $0.45 expiring 13 June 2023
Appendix 3Y pg. 1
Appendix 3Y
Change of Director’s Interest Notice
Mal Washer Nominees Pty Ltd <Mal Washer
Family A/C>
19,600,000 Ordinary Shares
Class changed
Ordinary Shares
Number acquired
270,000
100,000
150,000
255,000
-
(Dr Washer is a trustee and beneficiary of the trust)
Number disposed
Value/Consideration
Note: If consideration is non-cash, provide details and
estimated valuation
No. of securities held after change
$20,765.65
$7,986.90
$12,283.65
$20,321.22
Dr Stewart James Washer & Dr Patrizia Derna
Washer <The Washer Family Superannuation
Fund>
(Dr Washer is a trustee and beneficiary of the
1,325,599 Ordinary Shares
Dr Stewart James Washer & Dr Patrizia Derna
Washer <The Washer Family Trust>
28,400,000 Ordinary Shares
1,500,000 Unlisted Options
Mal Washer Nominees Pty Ltd <Mal Washer
Family A/C>
19,600,000 Ordinary Shares
Nature of change
On market purchases
superannuation fund)
(Dr Washer is a trustee and beneficiary of the Trust)
(Dr Washer is a trustee and beneficiary of the trust)
Example: on-market trade, off-market trade, exercise of
options, issue of securities under dividend reinvestment
plan, participation in buy-back
exercisable at $0.45 expiring 13 June 2023
Part 2 - Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder (if issued securities)
N/A
Date of change
N/A
No. and class of securities to which interest related prior
to change
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Note: Details are only required for a contract in relation to which the
interest has changed
Note: if consideration is non-cash, provide details and an estimated
valuation
+ See chapter 19 for defined terms
Appendix 3Y pg. 2
Appendix 3Y
Change of Director’s Interest Notice
Interest after changes
N/A
Part 3 – Closed Period
Were the interests in the securities or contracts
detailed above traded during a +closed period
where prior written clearance was required?
No
If so, was prior written clearance provided to
allow the trade to proceed during this period?
N/A
If prior written clearance was provided, on
what date was this provided?
N/A
+ See chapter 19 for defined terms
Appendix 3Y pg. 3
Share your feedback
Discover